Research and Development: Comparing Key Metrics for Bio-Techne Corporation and Veracyte, Inc.

A Decade of Innovation: R&D Trends in Bio-Techne and Veracyte

In the ever-evolving biotech industry, research and development (R&D) is the lifeblood of innovation. Over the past decade, Bio-Techne Corporation and Veracyte, Inc. have demonstrated significant commitment to R&D, albeit with different trajectories.

Bio-Techne has consistently increased its R&D spending, growing from approximately $31 million in 2014 to nearly $97 million by 2023. This represents a remarkable 212% increase, underscoring their dedication to advancing biotechnology solutions. In contrast, Veracyte's R&D expenses have surged from around $9.8 million in 2014 to $57 million in 2023, marking an impressive 482% growth.

While Bio-Techne's R&D investment is larger in absolute terms, Veracyte's rapid growth rate highlights its aggressive push into new research areas. However, data for 2024 is incomplete, leaving room for speculation on future trends. As these companies continue to innovate, their R&D strategies will be pivotal in shaping the biotech landscape.